Do patients having major abdominal surgery exhibit significant muscle wasting?

Muscle wAsting in Major Abdominal Surgery (MAMAS)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN96363642

Enrollment

Registered

2015-05-06

Start date

2016-03-21

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle wasting disease (myopenia) Musculoskeletal Diseases Myopenia

Interventions

1. The cross sectional area of the rectus femoris muscle (RFCSA) will be measured using an ultrasound machine before surgery and on day 7 (or day of discharge if earlier) 2. Handgrip strength (HGS) an

Eligibility

Sex/Gender

All

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: Current inclusion criteria as of 26/11/2018: 1. Patients presenting to Royal Surrey County Hospital (RSCH) for elective major abdominal surgery for cancer with predicted duration of surgery of >3 hours, such as resection of pancreas and small bowel or resection of organs of the female reproductive tract 2. Provide informed consent 3. Age =18 years Previous inclusion criteria: 1. Patients presenting to Royal Surrey County Hospital (RSCH) for elective major abdominal surgery for cancer (e.g. resection of whole/part of colon, rectum, stomach, oesophagus, liver, pancreas and small bowel; or resection of organs of the female reproductive tract) with predicted duration of surgery of >3 hours 2. Provide informed consent 3. Age =18 years

Exclusion criteria

Exclusion criteria: Current exclusion criteria as of 26/11/2018: 1. Neuromuscular condition 2. Invasively ventilated pre-operatively 3. Recent (<1 month) surgery, other than for the purposes of diagnosis/staging. 4. Unlikely to survive 1 month post-operatively Previous exclusion criteria: 1. Neuromuscular condition 2. Invasively ventilated pre-op 3. Recent (<1 month) surgery, other than for the purposes of diagnosis/staging. 4. Unlikely to survive 1 month post-operatively 5. Obesity

Design outcomes

Primary

Measure	Time frame
1. Characterise changes in muscle size and strength in patients undergoing major elective abdominal surgery for cancer at 2 stages: pre-operative and at day 7	—

Secondary

Measure	Time frame
1. Establish the relationship between observed changes in muscle size and strength 2. Establish the clinical sequelae of muscle wasting and weakness in relation to clinical outcomes 3. Elucidate risk factors for muscle wasting and muscle weakness 4. Assess relationship between muscle wasting and weakness 5. Assess recovery of muscle wasting and weakness between hospital discharge and week 6 and to elucidate risk factors for persistent or progressive change	—

Measure

Time frame

1. Establish the relationship between observed changes in muscle size and strength 2. Establish the clinical sequelae of muscle wasting and weakness in relation to clinical outcomes 3. Elucidate risk factors for muscle wasting and muscle weakness 4. Assess relationship between muscle wasting and weakness 5. Assess recovery of muscle wasting and weakness between hospital discharge and week 6 and to elucidate risk factors for persistent or progressive change

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 27, 2026